A Pilot Study of 18 F‐rhPSMA‐7.3‐PET/MRI to Reduce Mischaracterization of Active Surveillance and Focal Therapy Candidates With Occult Higher Risk Disease

Documenti analoghi

• Impact of Pelvic Lymph Node Dissection on Early Oncological Outcomes in Intermediate‐Risk Prostate Cancer Patients With Node‐Negative PSMA PET
  di: Baris Esen, et al.
  Pubblicazione: (2025)
• Role of Volumetric Parameters Derived From Ga‐68 PSMA PET‐CT in Predicting Treatment Response
  di: Ali Uyar, et al.
  Pubblicazione: (2025)
• [ 18 F] PSMA PET‐CT and [ 18 F] Choline PET‐CT in the Diagnosis of High‐Risk Localized Prostate Cancer: Comparation of Both Tests
  di: M. A. Tárraga‐Honrubia, et al.
  Pubblicazione: (2026)
• The Clinical Significance of Gallium‐68 PSMA‐11 PET‐Derived SUVmax in the Management of Metastatic Hormone‐Sensitive Prostate Cancer
  di: Cevat İlteriş Kıkılı, et al.
  Pubblicazione: (2026)
• Impact of definitive radiotherapy on metabolic response measured with 68Ga‐PSMA‐PET/CT in patients with intermediate‐risk prostate cancer
  di: Cem Onal, et al.
  Pubblicazione: (2024)